A clam immune active peptide and its screening method and application

Through the preparation of clam meat homogenate, complex protease enzymatic and bioinformatics tool screening, the immune-active peptide sequences with high immunomodulatory activity were screened, solving the problem of time-consuming, labor-intensive and active effects of isolation and purification methods in the prior art. , realizes efficient screening and production, and is used to improve product development for immune function.

CN118725034BActive Publication Date: 2024-12-03LUDONG UNIVERSITY
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411216587.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-09-02
Publication Date
2024-12-03
Estimated Expiration
2044-09-02

AI Technical Summary

Technical Problem

The existing methods for isolating and purifying immunoactive peptides have large human resources and material resources, long time, and have a great impact on product activity, making it difficult to efficiently screen out peptide sequences with high immunomodulatory activity.

Method used

Using the preparation of clam meat homogenate, enzymatic synthesis of complex proteases, preliminary separation of molecular exclusion chromatography, peptide spectrum identification and bioinformatics tool-assisted screening methods, peptide sequences with high immunomodulatory activity, such as SLLELDL and LEKNKDPLNET, were screened out, and chemically Synthesis method for production.

Benefits of technology

The immune-active peptide sequence of clams with high immunomodulatory activity was successfully screened for preparation of immunomodulatory agents, pharmaceutical compositions or nutritional products, which improved the efficiency of immune function regulation and the importance of product development.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118725034B_ABST
    Figure CN118725034B_ABST
Patent Text Reader

Abstract

The present invention discloses a clam immune active peptide and a screening method and application thereof, belonging to the field of active peptide technology. Through composite protease hydrolysis, molecular exclusion chromatography preliminary separation, LC-MS / MS peptide spectrum identification, bioinformatics tool prediction, peptide synthesis and activity verification, the immune active peptide sequences SLLELDL and LEKNKDPLNET with the best immunomodulatory activity are obtained. The clam immune active peptide of the present invention has good mouse macrophage RAW264.7 proliferation promoting activity and neutral red phagocytosis ability, and can be added as an immunomodulatory component to functional products such as immunomodulators and pharmaceutical compositions, which is of great significance to the development of new immune active peptide products.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of active peptides, and in particular relates to a clam immune active peptide and a screening method and application thereof. Background Art

[0002] Immunity is a specific physiological reaction that occurs when the body comes into contact with "antigenic foreign bodies" or "foreign molecules". For those with normal systemic immune function, there will be no inflammation or a mild reaction after infection with pathogens. For those with rapid and obvious reactions, they will soon return to normal. For those with low systemic immune function, infection and inflammation are more likely to occur. Although the inflammatory reaction is not obvious sometimes, it is easy to form chronic lesions in the long run. The occurrence of chronic inflammation can be prevented by supplementing the diet with immune active peptide substances to enhance autoimmunity.

[0003] At present, the most commonly used separation and purification methods for immunoactive peptides mainly include membrane separation and chromatography. Usually, ultrafiltration is used for primary separation to obtain components of target molecular weight; then the obtained components are separated for a second time by gel chromatography or ion exchange chromatography; finally, high performance liquid chromatography or reverse HPLC is used to separate and purify the separated target products. Traditional separation methods consume a lot of manpower and material resources, take a long time, and have a certain impact on the activity of the product. By combining bioinformatics tools, the screening efficiency of active peptides can be effectively improved.

[0004] Meretrix meretrix Meretrixmeretrix Linnaeus, also known as clams, is one of the important edible shellfish. Clam peptides are important bioactive ingredients in clam extracts. The use of marine shellfish clams to prepare immune active peptides is of great significance for enriching the types of marine protein source immune active peptides and enhancing the body's immunity. At the same time, it can provide a new channel for the deep processing and high-value transformation of marine protein resources. Summary of the invention

[0005] One of the purposes of the present invention is to provide a clam immune active peptide.

[0006] The second object of the present invention is to provide a method for screening the above-mentioned clam immune active peptides.

[0007] The third object of the present invention is to provide the application of the above-mentioned clam immune active peptide.

[0008] In order to achieve the above object, the technical solution of the present invention is as follows:

[0009] A clam immune active peptide, wherein the amino acid sequence of the immune active peptide is SLLELDL (Ser-Leu-Leu-Glu-Leu-Asp-Leu, as shown in SEQ ID NO.1) and / or LEKNKDPLNET (Leu-Glu-Lys-Asn-Lys-Asp-Pro-Leu-Asn-Glu-Thr, as shown in SEQ ID NO.2).

[0010] The screening of the above-mentioned clam immune active peptides comprises the following steps:

[0011] (1) Preparation of clam meat homogenate: Take a certain amount of clam meat, wash and dry it, and homogenize it in a high-speed tissue crusher for 3 times, each time for 30 seconds, to obtain a homogenate;

[0012] (2) Enzymatic hydrolysis with compound protease: 5 g of clam minced meat was added with ultrapure water at a material-liquid ratio of 1:6.2 (m:v, g / mL). The pH value was adjusted to 6.8, and then preheated to 45 °C. The compound protease was added and the enzyme addition amount was adjusted to an enzyme activity of 3493 U / g. The enzymatic hydrolysis was carried out for 3 h. After the enzymatic hydrolysis was completed, the enzyme was inactivated at 85 °C for 15 min, cooled, and centrifuged at 5000 r / min for 20 min. The supernatant was lyophilized for later use.

[0013] (3) Preliminary separation by size exclusion chromatography: The pre-treated Sephadex G-25 gel was loaded onto the column and equilibrated with ultrapure water as the mobile phase for 8 h. The freeze-dried clam hydrolysate was prepared into a solution of a certain concentration and filtered through a 0.45 μm filter membrane before loading. Ultrapure water was used as the mobile phase at a flow rate of 1 mL / min for isocratic elution separation. The sample was divided into ten components according to the elution time, and the components were collected and freeze-dried. The effects of each component on the relative proliferation rate of RAW 264.7 cells were determined. The four components with the highest activity were selected according to their activity, collected and combined, and the polypeptide amino acid sequence was identified after freeze-drying.

[0014] (4) Sequence identification of clam immune active peptides: The peptide spectrum of the simulated digestion products of clam protein was identified using the Thermo Fisher EASY-nLC1200 Q-Exactive LC-MS system;

[0015] (5) Bioinformatics tools assisted in the screening of clam immunologically active peptides: The novelty of the peptides was queried through the BIOPEP database, and the bioactivity of the unreported peptides was predicted through the Peptide Ranker tool. Sequences with a score of more than 0.5 were considered to have potential activity. The anti-inflammatory activity of the peptides was predicted through Pre AIP, and those with a score of more than 0.468 were considered to have high anti-inflammatory activity. Finally, the potential toxicity and physicochemical properties of the peptides were predicted through the Toxin Pred tool, and sequences without potential toxicity were subsequently synthesized and verified; the digestion resistance of the peptides was predicted through the PeptideCutter tool, and the cell membrane permeability was predicted through the CPP pred tool. Sequences with a score of more than 0.5 were considered to have complete transmembrane absorption potential;

[0016] (6) Determination of immunomodulatory activity: In vitro immunomodulatory activity tests were performed, including the effects of immunoactive peptides on the proliferation activity of mouse macrophages RAW 264.7 and the phagocytic ability of neutral red, to find the two peptides with the strongest immunomodulatory activity.

[0017] The composite protease is purchased from the market and is a Bacillus protease complex developed for hydrolyzing protein. It is produced by deep liquid fermentation of Bacillus subtilis and is concentrated, extracted, refined and composited. The main enzyme is alkaline protease.

[0018] Preferably, in step (1), after homogenizing the clams, the homogenate needs to be placed in an experimental refrigerator or immediately subjected to subsequent experiments to avoid long-term storage at room temperature resulting in degradation of protein and polypeptide components.

[0019] Preferably, in step (4), the components obtained in step (2) are separated using the Nano-HPLC liquid phase system EASY-nLC 1200 and then subjected to mass spectrometry analysis using a Q-Exactive mass spectrometer; the obtained mass spectrometry data are analyzed using the software MAXQUANT, and the obtained polypeptide sequence is compared with the Uniprot-Acipenser database to obtain the protein source of the peptide sequence.

[0020] Preferably, in step (5), the basic screening condition for the absence of potentially toxic sequences is: Peptide Ranker score>0.7 or Pre AIP score>0.468.

[0021] Preferably, in step (6), the method for determining the proliferation activity of RAW 264.7 is as follows: after culturing the cells for 24 hours, the supernatant is discarded, a certain concentration of polypeptide sample is added to the sample group, and an equal volume of serum-free culture medium is added to the blank group. After culturing for 8 hours, the proliferation rate is measured by CCK-8 method, and the absorbance value is measured at 450 nm; the cell proliferation rate = A / A0×100%; wherein A is the absorbance of the sample group, and A0 is the absorbance of the blank group.

[0022] Preferably, in step (6), the method for determining the neutral red phagocytosis ability of RAW 264.7 is as follows: after culturing the cells for 24 hours, the supernatant is discarded, different mass concentrations of polypeptide samples are added to the sample group, 1 μg / mL lipopolysaccharide is added to the positive control group, and an equal volume of serum-free culture medium is added to the blank group, and the cells are cultured for another 24 hours; the supernatant is discarded, neutral red staining solution is added, the cells are placed in an incubator for 20 minutes, the neutral red staining solution is aspirated, the cells are washed twice with phosphate buffer solution, 100 μL of cell lysis solution is added, the cells are placed at room temperature for 2 hours, and the absorbance value is measured at 540 nm. The neutral red phagocytosis rate = B / B0×100%, wherein B is the absorbance of the sample group and B0 is the absorbance of the blank group.

[0023] The clam immune active peptide of the present invention can be used in immunomodulators, pharmaceutical compositions or nutritional products for improving immune function.

[0024] In addition, the clam immune active peptide of the present invention can be synthesized and produced by solid phase synthesis methods during production and application, including but not limited to Fmoc-SPPS method, BOC-SPPS method, fragment condensation connection method and other feasible methods, so as to more efficiently obtain the clam immune active peptide.

[0025] Advantages of the present invention:

[0026] The present invention discloses a clam immune active peptide and a screening method thereof. The clam immune active peptide of the present invention is mainly obtained by composite protease hydrolysis, LC-MS / MS mass spectrometry identification, bioinformatics tool analysis prediction, peptide synthesis and activity verification screening. A total of 59 sequences were obtained through peptide spectrum identification, of which 1 active sequence has been reported and the remaining 58 have not been reported. Among the sequences, 1 Peptide Ranker score exceeds 0.5, and 4 Pre AIP scores exceed 0.468, all of which have no potential toxicity. After synthesis, the proliferation activity of mouse macrophage RAW 264.7 and the neutral red phagocytic ability evaluation experiment prove that the immunomodulatory activity of the polypeptide SLLELDL is the best, and the activity of LEKNKDPLNET is second. Both have high immunomodulatory activity and can be added as immunomodulatory components to functional products such as immunomodulators, pharmaceutical compositions or nutritional products, which is of great significance to the development of new immunoactive peptide products. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] FIG1 is a technical roadmap for preparing the immune active peptide of Meretrix meretrix in an embodiment of the present invention;

[0028] FIG2 is a diagram showing the molecular exclusion chromatography separation results of the clam immune active peptides in an embodiment of the present invention;

[0029] FIG3 is a graph showing the effect of size exclusion chromatography separation components on the proliferation activity of RAW264.7 cells in an embodiment of the present invention;

[0030] FIG4 is a graph showing the effect of synthetic peptides on the proliferation activity of RAW264.7 cells in an example of the present invention;

[0031] FIG5 is a graph showing the results of the phagocytic activity of the synthetic peptides on the neutral red in RAW264.7 cells according to an embodiment of the present invention;

[0032] FIG6 is a diagram showing the liquid phase detection results of the polypeptide SLLELDL in an embodiment of the present invention;

[0033] FIG7 is a diagram showing the mass spectrometry detection result of the polypeptide SLLELDL in an embodiment of the present invention;

[0034] FIG8 is a diagram showing the liquid phase detection results of the polypeptide LEKNKDPLNET in an embodiment of the present invention;

[0035] FIG9 is a diagram showing the mass spectrometry detection results of the polypeptide LEKNKDPLNET in an embodiment of the present invention;

[0036] FIG10 is a graph showing the results of promoting the proliferation activity of RAW264.7 cells by the polypeptides SLLELDL and LEKNKDPLNET in an embodiment of the present invention;

[0037] FIG. 11 is a graph showing the results of the polypeptides SLLELDL and LEKNKDPLNET promoting the phagocytic activity of neutrophil in RAW264.7 cells in an example of the present invention. DETAILED DESCRIPTION

[0038] The specific implementation methods of the present invention are further described below. The test methods used in the following examples are all conventional methods unless otherwise specified; the materials, reagents, etc. used are all reagents and consumables obtained from commercial channels unless otherwise specified; the equipment used is all conventional experimental equipment unless otherwise specified.

[0039] Embodiment 1:

[0040] A clam immune active peptide, the preparation technology route is as follows Figure 1 The specific steps include:

[0041] (1) Enzymatic preparation and size exclusion chromatography separation of clam immune active peptides: A certain amount of clam meat was washed and dried, and homogenized in a high-speed tissue crusher for 3 times, each time for 30 seconds to obtain a homogenate. 5 g of clam minced meat was added with ultrapure water at a solid-liquid ratio (m:v) of 1:6.2, and the pH value was adjusted to 6.8, and then preheated to 45 °C. Composite protease was added and the enzyme addition amount was adjusted to an enzyme activity of 3493 U / g, and the enzymatic hydrolysis was carried out for 3 h. After the enzymatic hydrolysis was completed, the enzyme was inactivated at 85 °C for 15 min, cooled, centrifuged at 5 000 r / min for 20 min, and the supernatant was freeze-dried for later use. The pre-treated Sephadex G-25 gel was loaded on the column, and ultrapure water was used as the mobile phase for 8 h. The freeze-dried clam enzymatic hydrolysate was prepared into a solution of a certain concentration, and then filtered through a 0.45 μm filter membrane and loaded. Ultrapure water was used as the mobile phase, and the flow rate was 1 mL / min for isocratic elution. The sample was divided into ten components according to the peak time ( Figure 2 ), were collected and freeze-dried, and the effects of each component on the relative proliferation rate of RAW 264.7 cells were determined ( Figure 3 ), select the components with better activity, collect and combine them, and identify the polypeptide amino acid sequence after freeze-drying.

[0042] (2) LC-MS / MS identification of peptide sequences: Mass spectrometry data were collected using the Nano-HPLC liquid phase system EASY-nLC 1200 (Thermo Fisher Scientific), and after separation, the samples were analyzed using a Q-Exactive mass spectrometer (Thermo Fisher Scientific). 18 Capture column (100 μm inner diameter, 2 cm length, 5- μm C18 ; SC001, Thermo Fisher Scientific) and C 18 Analytical column (75 μm inner diameter, 10 cm length, 3- μm C 18 SC2003, Thermo Fisher Scientific). The two mobile phases were buffer A (0.1% formic acid / 99.9% water) and buffer B (80% acetonitrile / 1% formic acid / 19% water), and the proportion of buffer B increased from 4% to 100% within 90 min. The flow rate was 250 nL / min. The scan was performed at m / z200 with a resolution of 70000, and the scan range was set from 400 to 1700 m / z. The 10 most abundant MS1 features were selected and high-energy collision dissociation fragmentation was performed at m / z 200 with a resolution of 17500. The ion injection time and ion target values ​​were set to 20 ms, 3E6 (survey scan) and 60 ms, 5E5 (MS / MS scan). Data were acquired using Xcalibur software (ThermoScientific).

[0043] (3) Bioinformatics tools assisted screening of clam immune active peptides:

[0044] First, the novelty of the peptides was queried through the BIOPEP database, and unreported peptides were further predicted. Secondly, the potential activity of the peptides was predicted through Peptide Ranker, and those with a score of more than 0.7 were considered to have potential activity. The anti-inflammatory activity of the peptides was predicted through PreAIP, and those with a score of more than 0.468 were considered to have potential anti-inflammatory activity. Finally, the potential toxicity and physicochemical properties of the peptides were predicted through the Toxin Pred tool, and only sequences that were considered to have no potential toxicity could be subsequently synthesized and verified. At the same time, the Peptide Cutter tool was used to predict the digestion resistance of the peptide. If there were no sites in the sequence that could be cut by pepsin (Pepsin pH 1.3 and pH>2.0, EC3.4.23.1), trypsin (Trypsin, EC3.4.21.4) and chymotrypsin (Chymotrypsin, EC3.4.21.1), the sequence was considered to have the potential to resist gastrointestinal digestion; the CPP pred tool was used to predict the cell membrane permeability of the peptide, and sequences with a score greater than 0.5 were considered to have complete transmembrane absorption potential.

[0045] A total of 59 sequences were obtained through peptide mapping, of which 1 active sequence has been reported, and the remaining 58 have not been reported. Among the sequences, 1 Peptide Ranker score exceeded 0.5, and 4 Pre AIP scores exceeded 0.468, all of which had no potential toxicity (Table 1).

[0046] Table 1 Screened potential immunogenic peptide sequences of Meretrix meretrix

[0047]

[0048] The sequences in Table 1 were selected for synthesis. The results of the RAW 264.7 cell proliferation activity assay and the neutral red phagocytosis assay were shown in Figure 4 and Figure 5 Through comparison, it was found that the polypeptide SLLELDL had the best immunomodulatory activity, followed by LEKNKDPLNET. Both peptides of the present invention can be added to immunomodulators to exert immunomodulatory effects.

[0049] Example 2: Chemical synthesis and activity verification of active peptides SLLELDL and LEKNKDPLNET

[0050] According to the mass spectrometry sequencing results in Example 1, Sangon Biotech (Shanghai) Co., Ltd. was commissioned to perform chemical synthesis. The liquid phase detection results and mass spectrometry detection results of the synthetic peptide SLLELDL were as follows: Figure 6 , Figure 7 As shown, the liquid phase detection results and mass spectrometry detection results of LEKNKDPLNET are shown in Figure 8 , Fig. 9 shown.

[0051] The immunomodulatory ability of the synthetic peptides SLLELDL and LEKNKDPLNET was evaluated by RAW 264.7 cell proliferation activity assay and neutral red phagocytosis assay.

[0052] (1) Effects of different concentrations of SLLELDL and LEKNKDPLNET on the relative proliferation rate of RAW264.7 cells

[0053] The CCK-8 method was used to determine the effects of different concentrations of SLLELDL and LEKNKDPLNET on the relative proliferation rate of RAW264.7 cells. Fig.10 As shown in the figure, SLLELDL can significantly enhance the proliferation activity of RAW264.7 cells, up to 146.96% (concentration 50 μg / mL); LEKNKDPLNET is slightly less effective, with the highest proliferation rate of 141.90% (concentration 2 μg / mL).

[0054] (2) Effects of different concentrations of SLLELDL and LEKNKDPLNET on the phagocytic ability of RAW264.7 cells

[0055] Neutral red phagocytosis assay was used to evaluate the effects of different concentrations of SLLELDL and LEKNKDPLNET on the phagocytic ability of macrophages. Fig.11 As shown in the figure, both SLLELDL and LEKNKDPLNET can significantly enhance the neutrophil red phagocytosis ability of RAW264.7 cells. At the same dose, the neutrophil red phagocytosis ability of the SLLELDL group was higher than that of the LEKNKDPLNET group, and the phagocytosis rate of the polypeptide group at the experimental dose was higher than that of the positive control group (lipopolysaccharide).

[0056] The above experiments have once again proved that the active peptides SLLELDL and LEKNKDPLNET of the present invention have strong immune activity and can be used to prepare products with improved immune function.

[0057] The above description is only a preferred embodiment of the present invention, which is only used to explain the present invention and does not limit the scope of implementation of the present invention. For those skilled in the art, other implementation methods can be obtained by replacement or change based on the technical content disclosed in this specification. All changes and improvements made on the principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A clam immune active peptide, characterized in that: The amino acid sequence of the immunologically active peptide is SLLELDL or LEKNKDPLNET.

Citation Information

Patent Citations

  • Clam bioactive peptide and its extraction method and use

    CN104311630A

  • Clam-derived antioxidant peptide as well as screening method and application thereof

    CN116836222A

  • Method for isolating and purifying functional peptide derived from shellfish and the use of the functional peptide

    KR1020110132498A

  • Method for producing clam active peptide

    WO2021142880A1